Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2002

View Archived Issues

Nascobal approved in Sweden for vitamin B12 malabsorption

Pfizer returns development rights for BioBypass to GenVec

Cell Pathways to distribute Sinclair's Gelclair oral gel in North America

BioSante licenses new hormone replacement product for female sexual dysfunction from Antares

Polyheal 1 enters clinical study for treatment of foot ulcers in diabetic neuropathic patients

Proof of principle demonstrated for steroid-mediated gene delivery

Restructuring announced by Valentis

Naturally occurring angiostatic agents identified by Scripps to have potential in eye diseases

Chemical-genomics collaboration announced by Acadia and Amgen

Cell Pathways updates phase IIa program of CP-461 in cancer

Human Genome Sciences submits IND for B-cell-targeting LymphoRad

Nymox expands Alzheimer's disease research with new agreement

Synagis approved in Japan; receives award in Germany

New antigen targets the focus of an ExonHit/Idec collaboration

Carrington collaborates with SRI on drug delivery technology

Cellegy readying launch of Anogesic

Biovail's extended-release pain medication successfully completes another phase III trial

Novel group of compounds identified as chemokine antagonists

Dihydropyridine-containing calcium channel antagonists from Ortho-McNeil

Celltech discloses potent and selective inhibitors of alpha4 integrins

Cyclohexylamines effective as NMDA receptor antagonists according to recent patents

Piperidine derivatives identified at AstraZeneca as modulators of chemokine receptors

Glutamate receptor-potentiating compounds claimed for use in cognition disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...